Coronavirus puts Big Pharma’s IP regime to the test [FT.com - Mergermarket]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: FT.com - Mergermarket
April 21, 2020Print this pageBe the first to know about every new story“Chaotic” is how Jorge Contreras, a law professor at the University of Utah, describes a struggle by companies and governments to navigate intellectual property law in the urgent search for Covid-19 treatments.When AbbVie, the drug company,dropped its patent rightsAbbVie’s move came after the Israeli government issued a compulsory licence — overriding normal patent protection — to allow the sale of copycat versions of the drug. For Israel to do this, say industry executives, shows that these are not normal times: the country is the home of Teva Pharmaceuticals and has an economy that is heavily dependent on R&D.Yet a growing number of higher-income countries — from to Chile — have indicated that they too are prepared to issue compulsory licences to secure adequate drug supplies.The industry views such moves with alarm. Severin Schwan, chief executive of Roche Holdings, says waiving IP “would be a disaster”. “If
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GSK (NYSE:GSK) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Deutsche Bank Maintains a Hold Rating on GSK plc (GSK) [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
GSK
Sec Filings
- 12/5/25 - Form 6-K
- 12/4/25 - Form 6-K
- 12/3/25 - Form 6-K
- GSK's page on the SEC website